Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947424 | 0.80 | NLRP3 (0.34) | NLRP3 | |
| SCHEMBL9947426 | 0.80 | NLRP3 (0.35) | NLRP3 | |
| SCHEMBL9947432 | 0.75 | NLRP3 (0.38) | NLRP3 | |
| SCHEMBL9947427 | 0.74 | MAPT (0.33) | NLRP3 | |
| SCHEMBL273727 | 0.72 | NLRP3 (0.43) | NLRP3 | |
| SCHEMBL9918133 | 0.72 | NLRP3 (0.39) | NLRP3 | |
| SCHEMBL9918131 | 0.71 | NLRP3 (0.35) | NLRP3 | |
| SCHEMBL272478 | 0.65 | NLRP3 (0.36) | NLRP3 | |
| SCHEMBL28996979 | 0.65 | NLRP3 (0.36) | NLRP3 | |
| SCHEMBL14911002 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468625-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9139519-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140349988-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140308260-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | EPICENTRX, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013052164-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013052803-A2 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | RADIORX, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012078992-A1 | ORGANONITRO COMPOUNDS FOR USE IN TREATING NON-HODGKIN'S LYMPHOMA AND LEUKEMIA, AND METHODS RELATING THERETO | RADIORX, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308260-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | HBB, HBG2, HBZ | NLRP3 3120/4885CYP2D6 1050/4885CYP2C19 311/4885 |
| US-20140349988-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | SLC22A8, SLCO2A1, SLCO2B1 | NLRP3 3952/4885CYP2D6 149/4885CYP2C19 96/4885 |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | SLC22A8, XPOT, NPM1 | NLRP3 3861/4885CYP2D6 477/4885CYP2C19 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.